IOV-SAR-201 trial: what clinicians have said so far
A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Soft Tissue Sarcoma
- NCT07741877 ↗
- Recruiting
- Iovance Biotherapeutics, Inc.
- Focused size, estimated: 1–150 verified statements once built
We haven't built an HCP commentary report on IOV-SAR-201 (lifileucel in previously treated advanced soft tissue sarcoma) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on IOV-SAR-201 so far
Podcasts, YouTube videos and posts on X and Bluesky we have indexed that name the trial. LinkedIn posts are read for reports and the Enterprise MCP, not yet for this index. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Indexed so far | |
|---|---|
| 6 posts on X, typically up to 26 once built |
The trial
ClinicalTrials.gov- Official title
- A Phase 2, Multicenter, Open-label Study of Lifileucel (Tumor-infiltrating Lymphocytes [TIL]) in Participants With Previously Treated Advanced Soft Tissue Sarcoma
- Phase
- Phase 2
- Status
- Recruiting
- Conditions
- Sarcoma; Soft Tissue Sarcoma (STS); Advanced Soft Tissue Sarcoma; Undifferentiated Pleomorphic Sarcoma (UPS); Dedifferentiated Liposarcoma (DDLPS)
- Interventions
- Lifileucel
- Arms
- Lifileucel · Experimental
- Enrollment
- 80 (estimated)
- Primary outcomes
- Objective Response Rate
- Sponsor
- Iovance Biotherapeutics, Inc.
- Start
- Oct 2, 2026
- Primary completion
- Sep 1, 2033 (estimated)
- Results posted
- No
- Registry record
- NCT07741877 · updated Oct 9, 2026